The two-compartment model of Rowland et al., (2) 
INTRODUCTION
Two types of well-defined quantitative models have been developed which attempt to describe the elimination of flowing substrates in the intact liver. One of these models has been termed the venous equilibration or "well-stirred" model (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) and has been developed mainly by Rowland (1, 2, l l, 12), Pang and Rowland (5) (6) (7) , and Wilkinson (3, 4, 8) . The other has been termed the sinusoidal perfusion or "parallel-tube" model (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) ~College of Pharmacy and Upjohn Center for Clinical Pharmacology, The University of Michigan, Ann Arbor, MI 48109. 2Address correspondence to Dr. John G. Wagner, Upjohn Center for Clinical Pharmacology, The University of Michigan Medical Center, Ann Arbor, MI 48109-1065. 73 Scheme I.
and has been mainly developed by Bass et al., (14, 16, (18) (19) (20) (21) (22) (23) (25) (26) (27) and Keiding et aL, (15, 17, 24, 28, 29) . The principal parts of the venous equilibration or "well-stirred" model were developed from the model of an isolated perfused organ system containing a reservoir and an eliminating organ and from the two-compartment open model with elimination from the peripheral compartment as depicted in Scheme I, but using the symbolism later used in this article rather than that of Rowland et al. (2) . Hence, in reality there are really three models, two of which are the so-called "well-stirred" model and the specific compartment model of Scheme I and these two are equivalent mathematically. In the "well-stirred" model one measures concentrations in the reservoir or compartment #1 of Scheme I, following either oral administration into compartment #2, or intravenous administration into compartment # 1.
Tucker (32) published a hydrodynamic analogue to the model of Scheme I and showed that all of the expectations of modern physiological pharmacokinetics may be derived from the analogue to the two-compartment model providing first order kinetics are obeyed.
We have extended the model of Rowland et al. (2) by replacing first order elimination by Michaelis-Menten elimination. We treat the steadystate in this article; a future article will consider single doses of drug given intravenously and orally. In subsequent articles we will show that considerable literature data on first-pass drugs may be explained by the simple models of Schemes I and II or obvious extensions of them.
The primary purpose of this article was to derive nonlinear equations involving Michaelis-Menten elimination to use in interpretation of literature (25) all the other articles involving the sinusoidal perfusion model (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (26) (27) (28) (29) apply to the steady-state. Hence, a secondary purpose of this article was to derive equations extending the venous equilibration model (5-7) to the steady-state so comparisons could be made between the venous equilibration model and the sinusoidal perfusion model with respect to the steady-state. However, the latter comparisons are not made in this article.
THEORY

Compartment Model
The model is a modification of the "upside-down" two-compartment open model of Rowland et aL (2) , altered to include Michaelis-Menten elimination kinetics. In this article, we discuss only the steady-state situation following administration of the drug at a zero order (constant) rate, Ro, either orally or intravenously, The equations developed assume complete availability of drug to the liver (i.e., FL = 1); if not, then FL would be less than unity and would multiply Ro when oral administration was considered. Since we are considering the steady-state then any number of other "tissue" or other compartments could be connected to compartments #1 and #2 by first order rate constants and the kinetic situation would not be changed. It is assumed that whole blood concentrations of drug are measured in compartment # 1, hence the equations developed contain the liver blood flow, designated as Q. If plasma concentrations were measured in compartment CA1, then the Q in this article would represent rQ where r is the blood/plasma concentration ratio of drug. The model of Scheme I considers only the formation of a single metabolite according to Micheaelis-Menten kinetics with maximal velocity, Vm, and Michaelis constant, Kin. However, in the general model (not shown) there may be parallel Michaelis-Menten and/or first order paths and parallel elimination of unchanged drug according to first order kinetics. In the latter case equations developed later would have to be modified.
Symbolism
Note that "1" refers to compartment #1, ss refers to steady-state, po refers to oral administration, IV refers to intravenous administration, z refers to zero order (constant rate) input. "Concentration" refers to whole blood concentration when Q is actually liver blood flow, and to plasma concentration when Q is equal to rQ (1) . Symbols are arranged alphabetically. 2s~ and ,--2ss. Corresponding concentrations for compartment #2. Ci:
The input concentration of drug to the liver compartment r~poz for intravenous or oral equivalent to Cfs v or ~1,~ administration, respectively.
Co:
The output concentration of drug from the liver compartc~1Vz rP~ for steady-state ment--equivalent to ,~2s~ or ,~2s, intraveneous or oral administration, respectively.
CLH:
The systemic or hepatic clearance = QCLd (Q + CL~).
CLi:
The intrinsic clearance of total drug for the model of Scheme II. 
First Order Model of Scheme I
Equal intercompartmental clearances (equivalent to our V~kx2 = V2k21) were assumed by Dedrick and Forrester (33), Perrier and Gibaldi (34), and Strong et al. (35) . The model of Dedrick and Forrester (33) is identical with the model of Scheme II. The derivations to follow clearly show that to obtain the accepted expressions for the systemic and oral clearances (2,3) using the classical method of writing the differential equations (shown below), one must assume that the intercompartmental clearances in the model of Schemes I and II are equal.
Intravenous Administration to Steady-State
The differential equations are as follows.
From Eq. (1) we get:
Substituting from Eq. (3) into Eq. (2) gives:
Ro-,2n.el'C.~2ss =0 (4) Now, the intrinsic clearance of compartment #2 of the model of Scheme I is the product of the volume, V2, and the first order elimination rate constant, kel. Hence, from Eq. (4) we obtain Eq. (5):
i~.2s s
Solving for , --2ssC' tvz in Eq. (3) we get:
V2k21
Substituting from Eq. (6) into Eq. (5) yields:
To obtain the accepted expression for hepatic clearance (2, 3, 5) from Eq.
(7) requires one to assume that:
Substituting from Eq. (8) into Eq. (7) gives:
Equation (9) may be rearranged to: 
.,
From Eqs. (8) and (19) one obtains for across the liver:
Substituting from Eqs. (8) and (21) into Eq. (20) yields Eq. (22) .
Ro Km + rlvz (22) "~ 2ss c~Wz in Eq. (22) (34) where the bars represent "absolute value of." Vm = K~CLi (35) Equation (31) 
Equations (29) through (33) have been derived in this article when input to the liver is truly zero order. This can be accomplished in an animal by infusing the drug at a constant rate into the portal vein. It can be accomplished approximately in man by administering an aqueous solution of a drug in small increments to steady-state, or by giving repetitive doses first at a high dose rate then switching to a slower dose rate (37) . However, Eqs. (29) Hence, if the rate R0 is the same intravenously and orally, then:
Solving for Km in Eq. (33) gives Eq. (38) .
Ro
Km-(38)
CLi -CLf~
Solving for V,, in Eq. (33) gives Eq. (39).
Ro
Vm = KmCL, ----
Cl-poz .t-, l s s I---
CL~
Equations (38) and (39) were given formerly by Wagner (38) .
In applying Eqs. (38) and (39) one can give a single low oral dose so that kinetics are first order and make an estimate of CLi as the ratio of the dose to the total area under the concentration-time curve in the usual manner.
Bioavailability and Extraction Ratios
Using the definition of bioavailability corresponding to input rate Ro, namely F,~, given under symbolism above, and using Eqs. ( 
the intrinsic hepatic clearance; corresponding to blood flow Q, is given by:
R ~O 1 K~ 1 1
Q+ CL~ Q V~ Q CL~
Equations (44), (45) , (47), and (49) were originally reported by Rowland et al. (2) and Wilkinson and Shand (3) . These equations are the limits of the nonlinear equations derived in this article; hence, the nonlinear equations are consistent with classical first order physiologic pharmacokinetics. This is emphasized by the equations in Table I .
Effect of Protein Binding and Red Cell Binding in Blood
All the previous equations have been written in terms of total (bound + free) drug concentrations in whole blood, but may equally as well be written T poz in terms of free (unbound) drug concentrations. In the latter case ,~lss and c,~ lvz . ~ ..'~rpozf ~c pTIVzf ,~lss are replaced oy J~t~Llss and Ju,--~ls~ , respectively, where fu is the fraction unbound in blood and the clearances are the corresponding clearances of free (unbound) drug. CLi would be replaced by fuCLY~, where CL f is the intrinsic clearance of unbound drug. Levy and Yacobi (40) experimentally showed that the total clearance of warfarin in rats was directly proportional to the free fraction, f~. This relationship is readily derived from 'the two mass balance Eqs. (50) and (51) and Eq. (49) as shown formerly (30) . 
Equation (49) may also be written as eq. (52).
O_LcL~
CL. = Q + f~ CL f
Equation (50) may also be written as Eq. (53).
Dpo = CLi(AUC O-OO)po
where,
Fi which is a fundamental equation of classical physiological pharmacokinetics (3).
Effect of Tissue Binding
As stated earlier, tissues may be attached to either compartments # 1 or #2 by a pair of first-order rate constants like k~2 and k21, and such tissues may bind the drug; such binding at steady-state would not change the kinetic situation described. However, the volumes, V~ and V2, would change since the tissues would hold some of the drug. The clever hydrodynamic analogue of Tucker (32) has compartments 1 and 2 of Scheme I as fluid compartments with goldfish (the analogy to tissues) swimming in the fluids in the two compartments. Nonlinear tissue binding could also be added to the basic model.
Dependence of Oral Bioavailability on Liver Blood Flow
It should be carefully noted that all the oral bioavailabilities, namely F~ and Fs~, are dependent upon liver blood flow, Q, even though the oral steady-state concentration and clearance are independent of liver blood flow.
Urinary Excretion of Unchanged Drug
If there were urinary excretion of unchanged drug according to firstorder kinetics Schemes I and II would be modified by showing an exit rate constant with rate constant, ke, off of compartment #1. Thus, the renal clearance of unchanged drug would be CLR = Vl ke. This would modify Eq. (19) by the addition of a term, -,--,R,--,ss, on the right-hand side. The net effect is that Eqs. (21) through (25) 
t,-~l 1"~ IVz
DISCUSSION
The models of Schemes I and II and obvious descendents, brought about by modification, appear to explain much of the clinical pharmacokinetic and physiologic observations made with first-pass drugs and reported in the literature. The senior author has surveyed the literature and believes most, if not all, first-pass drugs obey Michaelis-Menten elimination kinetics when given orally, and linear pharmacokinetics when administered intravenously. This is most likely the result of the difference in doses and the higher concentrations (as a result of both higher dose and lower volumes) when the drugs are given orally than when they are given intravenously. Pond and Tozer (13) did an excellent job of explaining this concentration difference with their Fig. 1 .
The most important equations derived in this article are Eqs. (25), (30), (33), (38) , (39), (41) , and (42) and Eqs. (62) and (69) of the Appendix. In applying the equations, measurement of whole blood drug concentrations are preferred, but plasma concentrations may also be measured (see under r and Q in Symbolism). To determine whether one or more of the equations apply the following are guidelines. On rectilinear graph paper plot the steady-state concentrations vs. dose rate. If the steady-state concentration increases more than proportionately with increase in dose rate then applicability of the equations is feasible. If the concentrations were measured after oral administration then plot Ro/CLPs 'z (i.e., ~rvo~.~ ~,-,lss/vs. Ro according to Eq. (33) ; if the data appear linear then obtain the least squares line and apply Eqs. (34) and (35) Equation (41) indicates that the steady-state bioavailability increases more than proportionately with increase in dose rate. When F~s is plotted vs. Ro on rectilinear graph paper the intercept on the ordinate scale is Fi (Eq. 44) then the plot curves upward and Fss ~ 1 as Ro ~ Vm. An example is shown in Fig. 1 for verapamil, where the values of Vm, Kin, and Q were estimated from the data of Freedman et al. (41) . Linearity of a plot of (1-Fss) (42) . Sometimes a parallel Michaelis-Menten and first order path also "pool" as shown by Wagner (43) . This is simply the result of a lack of sufficient information in the concentration-time data. However, such pooled parameter estimates are still useful for making clinical pharmacokinetic predictions.
An additional useful component may be built into a human or animal protocol. Concentrations can be continued to be measured after input has ceased so that fall-off data are collected. If applicable, such downslope concentration-time data may be fitted to the integrated form of the Michaelis-Menten equation via numerical integration of the MichaelisMenten equation. This procedure provides estimates of K,~ and V~ = Vm/V2 as performed by the senior author and his coworkers (44, 45) , where the V,, is obtained from the steady-state data as indicated above. An estimate of V2 is then given by V 2 = Vrn / Vtrn.
Future articles in the series will be concerned with single doses, evaluation of literature data according to the derived equations, and application of the model in toxicology and clinical pharmacokinetics and therapeutics. ACKNOWLEDGMENTS Gregory J. Szpunar and James J. Ferry were supported in part by the American Foundation for Pharmaceutical Education.
APPENDIX
Model modification when there is urinary excretion of unchanged drug according to first order kinetics is shown in Fig. 1A . Equation (30) indicates that in the absence of urinary excretion of unchanged drug the steady-state concentration after oral administration is independent of liver blood flow, Q. However, Eq. (69) indicates that when there is first-order elimination of unchanged drug (from compartment # 1 of the model of Scheme II) then the steady-state concentration after oral administration is dependent upon liver blood flow, Q.
